Prevalence and correlates of DSM-5 cannabis use disorder, 2012-2013: Findings from the National Epidemiologic Survey on Alcohol and Related Conditions-III
The Canadian product information for in-demand type 2 diabetes drugs Mounjaro and Trulicity has recently been updated with new warning language describing certain serious gastrointestinal risks, including gastroparesis (aka stomach paralysis)
Combining cagrilintide with tirzepatide could theoretically produce 20-30% body weight loss by targeting three distinct pathways (GIP, GLP-1, and amylin), but the lack of clinical data means dosing protocols are speculative, side effect profiles unknown, and safety unclear
Do not use RYBELSUS if: You or your family member has ever had MTC, or if you have an endocrine system condition called multiple endocrine neoplasia type 2 (MEN 2) You have had a serious allergic reaction to semaglutide or any of the ingredients in RYBELSUS
The official website is surprisingly vague on the matter of health claims
More research studies are still needed to assess the efficacy of retatrutide in the treatment of obesity and type 2 diabetes